The role of abuse-deterrent formulations in countering opioid misuse and abuse

被引:9
作者
Nguyen, V. [1 ]
Raffa, R. B. [1 ]
Taylor, R. [2 ]
Pergolizzi, J. V., Jr. [3 ,4 ,5 ]
机构
[1] Temple Univ, Sch Pharm, Philadelphia, PA 19122 USA
[2] NEMA Res, Bonita Springs, FL USA
[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[4] Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19122 USA
[5] Assoc Chron Pain Patients, Houston, TX USA
关键词
abuse; abuse-deterrent formulation; opioids; pain management; HYDROCHLORIDE; RESISTANT; CROSSOVER; THERAPY; TABLETS; ROUTES; IMPACT; SAFETY; SAMPLE; RISKS;
D O I
10.1111/jcpt.12337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is known and objective: Pain is a prevalent, and due to the ageing population, increasing medical problem. Opioids are frequently prescribed to meet the unmet medical need. Unfortunately, with the increase in the legitimate use of opioids, there has been a corresponding increase in abuse. A practical way to retain the pain relief afforded by opioids while decreasing opportunities for abuse is to make it more difficult to extract the opioid from the product or to make it less desirable to do so by designing an abuse-deterrent formulation ( ADF). We provide a brief overview of the strategies and early evidence related to opioid ADFs. Methods: Published and unpublished literature, websites, and other sources were searched for current opioid formulation options, including immediate-release and extended-release products. Each was summarized, reviewed and assessed. Results: The strategies that have been used to design the current opioid ADFs involve one or more of four approaches: a physical barrier; incorporation of an opioid receptor antagonist (e.g. naloxone) that self-limits opioid action when taken in excess amount; inclusion of a noxious agent that is released during inappropriate use; or a pro-drug. What is new and conclusions: Legitimate use of opioid analgesics carries with it certain risks, including the risk of abuse. The new ADFs utilize four major strategies and provide innovative additions to the armamentarium. They likely will become an important part of a comprehensive approach to limiting, although not eliminating, opioid misuse and abuse.
引用
收藏
页码:629 / 634
页数:6
相关论文
共 50 条
  • [31] Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations
    Turk, Dennis C.
    O'Connor, Alec B.
    Dworkin, Robert H.
    Chaudhry, Amina
    Katz, Nathaniel P.
    Adams, Edgar H.
    Brownstein, John S.
    Comer, Sandra D.
    Dart, Richard
    Dasgupta, Nabarun
    Denisco, Richard A.
    Klein, Michael
    Leiderman, Deborah B.
    Lubran, Robert
    Rappaport, Bob A.
    Zacny, James P.
    Ahdieh, Harry
    Burke, Laurie B.
    Cowan, Penney
    Jacobs, Petra
    Malamut, Richard
    Markman, John
    Michna, Edward
    Palmer, Pamela
    Peirce-Sandner, Sarah
    Potter, Jennifer S.
    Raja, Srinivasa N.
    Rauschkolb, Christine
    Roland, Carl L.
    Webster, Lynn R.
    Weiss, Roger D.
    Wolf, Kerry
    PAIN, 2012, 153 (10) : 1997 - 2008
  • [32] Development of Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate
    Ali, Sogra F. Barakh
    Dharani, Sathish
    Afrooz, Hamideh
    Mohamed, Eman M.
    Cook, Phillip
    Khan, Mansoor A.
    Rahman, Ziyaur
    AAPS PHARMSCITECH, 2020, 21 (03)
  • [33] The Effect of an Abuse-Deterrent Opioid Formulation (OxyContin) on Opioid Abuse-Related Outcomes in the Postmarketing Setting
    Coplan, P. M.
    Chilcoat, H. D.
    Butler, S. F.
    Sellers, E. M.
    Kadakia, A.
    Harikrishnan, V.
    Haddox, J. D.
    Dart, R. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (03) : 275 - 286
  • [34] What's holding back abuse-deterrent opioid formulations? Considering 12 US stakeholders
    Pergolizzi, Joseph V., Jr.
    Taylor, Robert, Jr.
    LeQuang, Jo Ann
    Raffa, Robert B.
    EXPERT OPINION ON DRUG DELIVERY, 2018, 15 (06) : 567 - 576
  • [35] Current approaches in tamper-resistant and abuse-deterrent formulations
    Mastropietro, David J.
    Omidian, Hossein
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2013, 39 (05) : 611 - 624
  • [36] Estimating Attractiveness for Abuse of a Not-Yet-Marketed "Abuse-Deterrent" Prescription Opioid Formulation
    Butler, Stephen F.
    Black, Ryan
    Serrano, Jill M. Grimes
    Folensbee, Lesley
    Chang, Alan
    Katz, Nathaniel
    PAIN MEDICINE, 2010, 11 (01) : 81 - 91
  • [37] Application of Hot Melt Extrusion Technology in the Development of Abuse-Deterrent Formulations: An Overview
    Butreddy, Arun
    Nyavanandi, Dinesh
    Narala, Sagar
    Austin, Fischer
    Bandari, Suresh
    CURRENT DRUG DELIVERY, 2021, 18 (01) : 4 - 18
  • [38] Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting
    Peacock, Amy
    Larance, Briony
    Bruno, Raimondo
    Pearson, Sallie-Anne
    Buckley, Nicholas A.
    Farrell, Michael
    Degenhardt, Louisa
    ADDICTION, 2019, 114 (03) : 389 - 399
  • [39] Development of Methamphetamine Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate
    Dharani, Sathish
    Ali, Sogra F. Barakh
    Afrooz, Hamideh
    Mohamed, Eman M.
    Cook, Phillip
    Khan, Mansoor A.
    Rahman, Ziyaur
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (03) : 1338 - 1346
  • [40] Emerging Trends in Abuse-Deterrent Formulations: Technological Insights and Regulatory Considerations
    Rana, Dhwani
    Salave, Sagar
    Benival, Derajram
    CURRENT DRUG DELIVERY, 2022, 19 (08) : 846 - 859